瑞巴派特三联疗法用于胃溃疡伴胃出血的临床观察OA北大核心CSTPCD
Clinical Observation of Rebamipide Triple Therapy in the Treatment of Gastric Ulcer with Bleeding
目的:观察瑞巴派特三联疗法用于胃溃疡伴胃出血的疗效和安全性.方法:130例胃溃疡伴胃出血患者随机分为对照组(65例)和观察组(65例).对照组患者给予奥美拉唑肠溶胶囊20 mg,口服,每日2次+铝碳酸镁片500 mg,口服,每日1次;观察组患者在对照组治疗的基础上给予瑞巴派特片0.1 g,口服,每日3次.两组疗程均为12周.观察两组患者的临床疗效,嗳气、腹痛、腹胀、呕血/便血缓解时间,治疗前后临床症状评分,再出血发生情况及不良反应发生情况.结果:…查看全部>>
OBJECTIVE:To observe the efficacy and safety of rebamipide triple therapy in the treatment of gastric ulcer with bleeding. METHODS:130 patients with gastric ulcer with bleeding were randomly divided into control group(65 cases)and obser-vation group(65 cases). Control group received Omeprazole enteric-coated capsule 20 mg,orally,twice a day+Aluminum magne-sium carbonate tablet 500 mg,orally,once a day;observation group was additionally received Rebamipide ta…查看全部>>
朱晨宇;杨振华
三峡大学第一临床医学院/宜昌市中心人民医院胃肠外科,湖北宜昌 443000三峡大学第一临床医学院/宜昌市中心人民医院胃肠外科,湖北宜昌 443000
医药卫生
瑞巴派特奥美拉唑铝碳酸镁胃溃疡胃出血疗效安全性
RebamipideOmeprazoleAluminum magnesium carbonateGastric ulcerGastric bleedingEfficacySafety
《中国药房》 2017 (6)
766-769,4
评论